Draw attention to the teratogenic effect of DMD in MS treatment

More than 2.3 million people are affected by Multiple Sclerosis (MS) worldwide. Since the 1990s, disease modifying drug (DMD) has been developing increasingly. With more and more clinical applications, more and more attention has been paid to the adverse effects of DMD in the treatment of MS. DMD selection for patients with MS during pregnancy is one of the most important topics for neuroimmunologists and obstetrics. This comment is mainly based on our published and forthcoming data.

The number of cases with extraocular muscle involvement (eye movement disorder, diplopia, blepharoptosis) was 5. The number of cases with initial extraocular muscle involvement was 3.
The number of patients with optic nerve involvement (vision disturbance, pupil) was 25.
The number of patients with initial optic nerve involvement was 19.
The number of patients who had VEP examined was 59. The number of patients with prolonged P-100 incubation period was 43. The number of patients who had BAEP inspected was 59. The number of patients with abnormal BAEP was 10. The number of patients with 3-5 wave elongation was 9.
The number of patients who had SSEP examined was 59. The number of patients with abnormal SSEP was 26. The number of patients whose lesions located in cervical enlargement and above was 18. The number of patients whose lesions located between cervical and lumbar enlargement was 6. The number of patients whose lesions located in lumbar enlargement and below was 5.
The number of patients who had MRI examined was 69. The number of patients with abnormal MRI was 62. The number of patients whose lesions located in cortical and juxtacortex was 18. The number of patients whose lesions located in periventricular was 19. The number of patients whose lesions located in infratentorial was 10. The number of patients whose lesions located in spinal cord was 3.
Although there is no cure for MS, effective strategies are available to treat exacerbations (relapses), modify the disease course, enhance their comfort, improve symptoms and quality of life.
DMDs have been shown to be effi cacious in reducing relapse frequency in MS, have been shown to have a decreased risk of relapse, fewer emergency room visits, fewer severe relapses, fewer hospitalizations, fewer neuropsychological issues, lower costs, and increased quality of life.
There has been no report of teratogenic effect of DMD in china. (http://www.cnki.net/). Teratogenic effect of drug is very diffi cult to investigate, therefore there is rare report of teratogenic effect of drugs treating MS. Not have being discovered does not mean not exist. Even some is lethal. Call for paying attention to the teratogenic effect of DMD for MS is very important.
Draw special attention to our knowledge, no existing studies in the published literature have described the relationship between the use of glatiramer acetate and congenital diaphragmatic agenesis.